A Multicenter, Open-Label Extension Study of WVE-210201 in Patients previously enrolled in WVE-DMDX51-001
Phase of Trial: Phase I
Latest Information Update: 21 Dec 2018
At a glance
- Drugs WVE 210201 (Primary)
- Indications Duchenne muscular dystrophy
- Focus Adverse reactions
- Sponsors WaVe life Sciences
- 09 Nov 2018 According to a WaVe life Sciences media release, the company expects to present interim analysis of dystrophin expression in muscle biopsies from this trial in second half of 2019.
- 24 Aug 2018 New trial record
- 09 Aug 2018 Status changed to recruiting, according to a WaVe life Sciences media release.